Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial.

Yasuyoshi MiyataToshifumi TsurusakiYasushi HayashidaYushi ImasatoKosuke TakeharaDaiyu AokiMasaharu NishikidoJunichi WatanabeKensuke MitsunariTomohiro MatsuoKojiro OhbaKeisuke TaniguchiHideki Sakainull null

Published in: BJU international (2021)

Our randomised clinical trial suggested that intravesical therapy with MMC and Ara-C is useful and safe for patients with intermediate-risk NMIBC. Increase in urinary pH with Ara-C is speculated as a mechanism for increased anti-cancer effects.

Keyphrases

muscle invasive bladder cancer
clinical trial
double blind
open label
phase ii
study protocol
phase iii
placebo controlled
stem cells
bone marrow
smoking cessation